Chemotherapy Induced Neutropenia (CIN) -Market Insights, Epidemiology and Market Forecast-2023

Friday, November 10, 2017 Environmental Health
Email Print This Page Comment bookmark
Font : A-A+

DelveInsight's "Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United

LONDON, Nov. 9, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4985942

States,

Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer indications till 2023.

The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers.

Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the worldwide CIN market is estimated to increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Download the full report: https://www.reportbuyer.com/product/4985942

About Reportbuyer  Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com

For more information:Sarah SmithResearch Advisor at Reportbuyer.comEmail: [email protected]Tel: +44 208 816 85 48Website: www.reportbuyer.com

 

View original content:http://www.prnewswire.com/news-releases/chemotherapy-induced-neutropenia-cin--market-insights-epidemiology-and-market-forecast-2023-300553566.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store